Literature DB >> 1967273

CD4+ T cell-mediated killing of MHC class II-positive antigen-presenting cells. I. Characterization of target cell recognition by in vivo or in vitro activated CD4+ killer T cells.

P Erb1, D Grogg, M Troxler, M Kennedy, M Fluri.   

Abstract

Ag-specific as well as Ia-restricted killing of certain APC by CD4+ T cells was investigated. The CD4-mediated killing is not only a characteristic of in vitro long term cultured T cell lines or clones, but is also manifest after in vivo priming. Thus, CD4+ killer T cells are generated in vivo as well. CD4+ killer T cells are detected in the Th1, but not in the Th2 subset, and they do not appear to lyse Ia+ APC or bystander cells by a pathway mediated by secreted T cell factors. The latter observation is demonstrated by cold target inhibition experiments as well as by the failure of puromycin to inhibit killing, if applied in doses which completely block lymphokine secretion. Ia+ APC differ in their susceptibility to lysis. Transformed APC are usually better lysed than nontransformed APC. Unstimulated B cells are not killed, while LPS-stimulated B cell blasts are killed. The results of cold target inhibition and bystander killing experiments suggest that CD4+ killer T cells are activated by the common pathway, i.e., by Ag presented in the context of Ia, but killing requires the recognition of additional determinant(s) on APC. It is proposed that these killing-inducing determinants are continuously expressed on most transformed Ia+ cells and on nontransformed but stimulated APC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967273

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines.

Authors:  Barbara Lotti; Thomas Wendland; Hansjakob Furrer; Nikhil Yawalkar; Salome von Greyerz; Karin Schnyder; Marlène Brandes; Pietro Vernazza; Ralf Wagner; Thi Nguyen; Eric Rosenberg; Werner J Pichler; Christian Brander
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

2.  Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles.

Authors:  R Nisini; M Paroli; D Accapezzato; F Bonino; F Rosina; T Santantonio; F Sallusto; A Amoroso; M Houghton; V Barnaba
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model.

Authors:  T Cao; P Meuleman; I Desombere; M Sällberg; G Leroux-Roels
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  The influence of allo-class II MHC-specific Th2 cells on the generation of CD4 and CD8 cytotoxic T cells to associated class I and class II MHC alloantigen.

Authors:  P J Wood; I A Cossens
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

5.  EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function.

Authors:  K Bickham; C Münz; M L Tsang; M Larsson; J F Fonteneau; N Bhardwaj; R Steinman
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

6.  CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection.

Authors:  M Iwashiro; K Peterson; R J Messer; I M Stromnes; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.

Authors:  J Quddus; K J Johnson; J Gavalchin; E P Amento; C E Chrisp; R L Yung; B C Richardson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.

Authors:  Y Moriya; H Sato; K Ito; M Saito; T Yoshida; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 9.  The optimization of helper T lymphocyte (HTL) function in vaccine development.

Authors:  J Alexander; J Fikes; S Hoffman; E Franke; J Sacci; E Appella; F V Chisari; L G Guidotti; R W Chesnut; B Livingston; A Sette
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

10.  Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.